Rifampicin-Resistant Mycobacterium tuberculosis Among Patients with Presumptive Tuberculosis in Addis Ababa, Ethiopia

Figures & data

Table 1 Demographic and Clinical Characteristics of Study Participants at St. Peter Tuberculosis Specialized Hospital, Addis Ababa, Ethiopia, from 2016 to 2018

Variables	Category	Frequency	Percentage
Sex	Female	5645	44.5
	Male	7040	54.5
Age, mean±SD		40.3±18.7
Age in years	≤5	62	0.5
	6–20	1165	9.2
	21–40	5527	43.6
	41–60	3848	30.3
	61–80	1883	14.8
	>80	200	1.6
HIV status	Positive	775	6.1
	Negative	646	5.1
	Unknown	11,264	88.8
TB category	New	10,772	85
	Relapse	1713	13.5
	Treatment after failure of the first	132	1
	Treatment after lost to follow-up	68	0.5

Table 2 Association of Clinical and Sociodemographic Factors with M. Tuberculosis Among Presumptive TB Patients Who Visited St. Peter Tuberculosis Specialized Hospital from 2016 to 2018 (n=12,685)

Variables		M. tuberculosis Status		P-value
	Category	MTB-Positive, n (%)	MTB-Negative, n (%)
Sex	Female	650 (11.5)	4995 (89.5)	0.782
	Male	1064 (15.1)	5976 (84.9)
Age in years	≤5	5 (8.1%)	57 (91.9)
	6-20	264 (22.7)	901 (77.3)	0.039
	21–40	1037 (18.7)	4490 (81.3)
	41–60	201 (5.2)	3647 (94.8)
	61–80	174 (9.2)	1709 (81.8)
	>80	33 (16.5)	167 (73.5)
HIV status	Positive	128 (16.5)	647 (83.5)	>0.05
	Negative	138 (21.3)	508 (79.7)
	Unknown	1448 (12.85)	9816 (87.25)
TB category	New cases	1415 (13.1)	9357 (86.9)	0.042
	Relapse	241 (14.1)	1472 (85.9)
	Treatment after failure of first	45 (34.1)	87 (65.9)
	Treatment after lost to follow-up	13 (19.1)	55 (79.9)

Table 3 Association of RR-MTB with Sociodemographic and Clinical Factors of Patients

Variables		RR Status			P-value
	Category	Positive, n (%)	Indeterminate, n (%)	Negative, n (%)
Total MTB cases		169 (9.8)	20 (1.2)	1525 (89)
Gender	Female	67 (10.3)	7 (1.1)	576 (88.6)	0.81
	Male	102 (9.6)	13 (1.2)	949 (89.2)
Age in years	≤5	1 (20)	–	4 (80%)	<0.001
	6–20	27 (10.2)	5 (1.9)	232 (87.9)
	21–40	109 (10.5)	8 (0.8)	920 (88.7)
	41–60	25 (12.4)	2 (0.1)	174 (86.5)
	61–80	4 (2.2)	4 (2.2)	166 (95.4)
	>80	3 (9.1)	1 (3)	29 (87.9)
HIV status	Positive	16 (12.5)	5 (3.9)	107 (83.6)	0.032
	Negative	10 (7.2)	12 (8.7)	116 (84.1)
	Unknown	133 (9.2)	3 (0.2)	1312 (90.6)
TB category	New cases	118 (8.3)	6 (0.4)	1291 (91.3)	0.025
	Relapse	38 (15.76)	9 (3.7)	194 (80.5)
	Treatment after failure	10 (22.2)	3 (6.7)	32 (71.1)
	Treatment after lost to follow-up	3 (23.1)	2 (15.4%)	8 (61.5)

Figure 1 Trend of MTB and rifampicin resistance from 2016 to 2018 at St. Peter Tuberculosis Specialized Hospital, Addis Ababa, Ethiopia.